Endo Acquires Rights to Trimel’s Natesto Testosterone Nasal Gel

Endo Acquires Rights to Trimel’s Natesto Testosterone Nasal Gel
Endo International has announced it acquired the rights to Natesto, a testosterone nasal gel that acts as replacement therapy in men diagnosed with hypogonadism, from Trimel BioPharma SRL. Natesto, approved by the U.S. Food and Drug Administration (FDA) earlier this year, is an androgen that can be used as a therapy for patients suffering from a

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *